The anti-angiogenic basis of metronomic chemotherapy

Nature Reviews Cancer

Volumn 4, Issue 6, 2004, Pages 423-436

  Kerbel, Robert S ^a   Kamen, Barton A ^b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BA 1 12 9566; BATIMASTAT; BEVACIZUMAB; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DALTEPARIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; FUMAGILLOL CHLOROACETYLCARBAMATE; GROWTH FACTOR; IRINOTECAN; MATRIX METALLOPROTEINASE INHIBITOR; MERCAPTOPURINE; METHOTREXATE; MONOCLONAL ANTIBODY DC101; PACLITAXEL; ROFECOXIB; SEMAXANIB; TAXANE DERIVATIVE; THROMBOSPONDIN 1; TOPOTECAN; TRASTUZUMAB; UFT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 2; VINBLASTINE;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; BONE MARROW DEPRESSION; BONE MARROW SUPPRESSION; CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CELL PROLIFERATION; CELL TYPE; CHRONIC DRUG ADMINISTRATION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; GENITAL SYSTEM DISEASE; HAIR LOSS; HUMAN; INTESTINE INJURY; LOW DRUG DOSE; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; METRONOMIC CHEMOTHERAPY; MITOSIS INHIBITION; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVIEW; TECHNIQUE; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

EID: 2942615257     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1369     Document Type: Review

References (142)

1. Schiller, J. H. et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346, 92-98 (2002).
2. Leaf, C. Why we're losing the war on cancer (and how to win it). Fortune 149, 77-97 (2004).
3. Hanahan, D., Bergers, G. & Bergsland, E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 105, 1045-1047 (2000). An insightful commentary in which the term 'metronomic' was coined to describe prolonged therapy using frequent administration of low doses of chemotherapy as an anti-angiogenic treatment strategy.
4. Gasparini, G. Metronomic scheduling: the future of chemotherapy? Lancet Oncol. 2, 733-740 (2001).
5. Kamen, B. A., Rubin, E., Aisner, J. & Glatstein, E. High-time chemotherapy or high time for low dose. J. Clin. Oncol. 18, 2935-2937 (2000).
6. Kerbel, R. S., Klement, G., Pritchard, K. I. & Kamen, B. A. Continuous low-dose anti-angiogenic (metronomic) chemotherapy: from the research laboratory into the oncology clinic. Ann. Oncol. 13, 12-15 (2002).
7. Nieto, Y. The verdict is not in yet. Analysis of the randomized trials of high-dose chemotherapy for breast cancer. Haematologica 88, 201-211 (2003).
8. Roche, H., Viens, P., Biron, P., Lotz, J. P. & Asselain, B. High-dose chemotherapy for breast cancer: the French PEGASE experience. Cancer Control 10, 42-47 (2003).
9. Piccart-Gebhart, M. J. Mathematics and oncology: a match for life? J. Clin. Oncol. 21, 1425-1428 (2003).
10. Tuma, R. S. Dosing study seen as victory for clinical trials, mathematical models. J. Natl Cancer Inst. 95, 254-255 (2003).
11. Citron, M. L. et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol. 21, 1431-1439 (2003).
12. Lokich, J. Phase I clinical trial of weekly combined paclitaxel plus docetaxel in patients with solid tumors. Cancer 89, 2309-2314 (2000).
13. Burstein, H. J. et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J. Clin. Oncol. 18, 1212-1219 (2000).
14. Aihara, T., Kim, Y. & Takatsuka, Y. Phase II study of weekly docetaxel in patients with metastatic breast cancer. Ann. Oncol. 13, 286-292 (2002).
15. Tulpule, A. et al. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer 95, 147-154 (2002).
16. Klement, G. et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105, R15-R24 (2000).
17. Bertolini, F. et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 63, 4342-4346 (2003). A possible explanation for the repair of the tumour neovasculature during the prolonged drug-free break periods between cycles of MTD chemotherapy. Repair is mediated through mobilization of circulating endothelial progenitor cells, which is circumvented by metronomic dosing.
18. Bello, L. et al. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res. 61, 7501-7506 (2001). An excellent preclinical study comparing the effects of a metronomic protocol using two different chemotherapeutic drugs (carboplatin and etoposide) to a more conventional, high-dose regimen of the same drugs. It showed improved survival times for patients on the metronomic regimen, including when this was combined with an anti-angiogenic agent for the treatment of a rodent model of glioma.
19. Man, S. et al. Antitumor and anti-angiogenic effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res. 62, 2731-2735 (2002). A simple, convenient and humane method of administering low doses of a drug (cyclophosphamide) on a daily basis over long periods to test metronomic chemotherapy in mouse models of cancer.
20. Hahnfeldt, P., Folkman, J. & Hlatky, L. Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J. Theor. Biol. 220, 545-554 (2003).
21. Stoll, B. R., Migliorini, C., Kadambi, A., Munn, L. L. & Jain, R. K. A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for anti-angiogenic therapy. Blood 102, 2555-2561 (2003).
22. Browder, T. et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60, 1878-1886 (2000). A seminal study that first defined the basic principles of metronomic or 'anti-angiogenic' chemotherapy and outlined a strategy for treating drug-resistant tumours by altering the dosing and scheduling of chemotherapy, so as to target the neovasculature of the tumour more effectively.
23. Miller, K. D., Sweeney, C. J. & Sledge, G. W. Redefining the target: chemotherapeutics as antiangiogenics. J. Clin. Oncol. 19, 1195-1206 (2001).
24. Hurwitz, H. et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (Irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc. Am. Soc. Clin. Oncol. 21, A3646 (2003).
25. Hurwitz, H. et al. Addition of bevacizumab (rhuMab VEGF) to bolus IFL in the first line treatment of patients with metastatic colorectal cancer: results of a randomized phase III trial. N. Engl. J. Med. (in the press). The results of a pivotal randomized Phase III clinical trial in which bevacizumab, combined with a standard chemotherapy regimen, significantly improved the survival times of patients with advanced-stage metastatic colorectal carcinoma. This trial led to the approval of bevacizumab by the Food and Drug Administration on 26 February, 2004.
26. Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
27. Eberhard, A. et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 60, 1388-1393 (2000).
28. Crawford, J. et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N. Engl. J. Med. 325, 164-170 (1991).
29. Kerbel, R. S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays 13, 31-36 (1991). A commentary that first outlined the concept that it should be possible to treat drug-resistant tumours by virtue of the effects of chemotherapy on the dividing endothelial cells of the genetically stable, growing neovasculature of a tumour.
30. Sweeney, C. J. et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 61, 3369-3372 (2001).
31. Tran, J. et al. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc. Natl Acad. Sci. USA 99, 4349-4354 (2002). A study showing that VEGF can induce the equivalent of a multidrug-resistant phenotype in human vascular endothelial cells in vitro. This is because of the upregulation of the anti-apoptotic effector survivin when such cells are exposed to modest concentrations of the drugs in the presence of VEGF.
32. Takahashi, N., Haba, A., Matsuno, F. & Seon, B. K. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res. 61, 7846-7854 (2001).
33. Hamano, Y. et al. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res. 64, 1570-1574 (2004). Another important study showing that the antitumour effects of metronomic cyclophosphamide are mediated indirectly through induction of thrombospondin-1, produced by tumour cells and infiltrating stromal cells in tumours (B16 melanomas).
34. Bocci, G., Francia, G., Man, S., Lawler, J. & Kerbel, R. S. Thrombospondin-1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc. Natl Acad. Sci. USA 100, 12917-12922 (2003). First study to show an indirect mechanism that accounted for the anti-angiogenic effects induced by low-dose metronomic chemotherapy. This might be a paradigm for how some other angiogenesis inhibitors work.
35. Emmenegger, U. et al. A comparative analysis of low dose metronomic cyclophosphamide reveals absent or low grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res. (in the press).
36. Gately, S. & Kerbel, R. Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J. 7, 427-436 (2001).
37. Kakolyris, S. et al. Treatment of non-small-cell lung cancer with prolonged oral etoposide. Am. J. Clin. Oncol. 21, 505-508 (1998).
38. Alvarez, A. et al. Weekly taxol (T) in patients who had relapsed or remained stable with T in a 21 day schedule. Proc. Am. Soc. Clin. Oncol. 17, A188 (1998).
39. Fennelly, D. et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J. Clin. Oncol. 15, 187-192 (1997).
40. Greco, F. A. Docetaxel (Taxotere) administered in weekly schedules. Semin. Oncol. 26, 28-31 (1999).
41. Link, M. P., Shuster, J. J., Donaldson, S. S., Berard, C. W. & Murphy, S. B. Treatment of children and young adults with early-stage non-Hodgkin's lymphoma. N. Engl. J. Med. 337, 1259-1266 (1997).
42. Kamen, B. A. Why more 6-mercaptopurine? Semin. Hematol. 28, 12-14 (1991).
43. Crist, W. M. et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J. Clin. Oncol. 19, 3091-3102 (2001).
44. Grundy, P. E. et al. Principles and practice of pediatric oncology (eds Pizzo, P. A. & Poplack, D. G.) 865-893 (Lippincott Williams and Wilkins, Philadelphia, 2002).
45. Camitta, B. M. & Kamen, B. A. Childhood acute lymphoblastic leukemia (ed. Pui, C. H.) 357-364 (Human Press Ltd, Totowa, New Jersey, 2003).
46. Joussen, A. M., Kruse, F. E., Volcker, H. E. & Kirchhof, B. Topical application of methotrexate for inhibition of corneal angiogenesis. Graefes Arch. Clin. Exp. Ophthalmol. 237, 920-927 (1999).
47. Hirata, S., Matsubara, T., Saura, R., Tateishi, H. & Hirohata, K. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum. 32, 1065-1073 (1989).
48. Presta, M. et al. Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process. Cancer Res. 59, 2417-2424 (1999).
49. Colleoni, M. et al. Low dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann. Oncol. 13, 73-80 (2002). Description of a Phase II clinical trial of metronomic chemotherapy involving prolonged administration of daily oral low-dose cyclophosphamide and low-dose methotrexate, with no breaks, to treat patients with advanced metastatic breast cancer. This result has spawned several other clinical trials, many involving addition of an anti-angiogenic drug.
50. Garber, K. Could less be more? Low-dose chemotherapy goes on trial. J. Natl. Cancer Inst.. 94, 82-84 (2002).
51. Spieth, K., Kaufmann, R. & Gille, J. Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. Cancer Chemother. Pharmacol. 52, 377-382 (2003).
52. Glode, L. M. et al. Metronomic therapy with cyclophosphamide and dexamethasone for prostate cancer. Cancer 98, 1643-1648 (2003).
53. Witte, L. et al. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev. 17, 155-161 (1998).
54. Alon, T. et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nature Med. 1, 1024-1028 (1995).
55. Benjamin, L. E., Golijanin, D., Itin, A., Pode, D. & Keshet, E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103, 159-165 (1999).
56. Gerber, H. P. et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 273, 30336-30343 (1998).
57. Nor, J. E. & Polverini, P. J. Role of endothelial cell survival and death signals in angiogenesis. Angiogenesis 3, 101-116 (1999).
58. Mandriota, S. J. et al. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J. Biol. Chem. 270, 9709-9716 (1995).
59. Tran, J. et al. Marked induction of the IAP family anti-apoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem. Biophys. Res. Commun. 264, 781-788 (1999).
60. Mesri, M. et al. Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am. J. Pathol. 158, 1757-1765 (2001).
61. Castilla, M. A. et al. Role of vascular endothelial growth factor (VEGF) in endothelial cell protection against cytotoxic agents. Life Sci. 67, 1003-1013 (2000).
62. Gorski, D. H. et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59, 3374-3378 (1999).
63. Teicher, B. A., Sotomayor, E. A. & Huang, Z. D. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res. 52, 6702-6704 (1992).
64. Kakeji, Y. & Teicher, B. A. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest. New Drugs 15, 39-48 (1997).
65. Klement, G. et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug resistant human breast cancer xenograft. Clin. Cancer Res. 8, 221-232 (2002).
66. Tashiro, T. et al. Responsiveness of human lung cancer/nude mouse to antitumor agents in a model using clinically equivalent doses. Cancer Chemother Pharmacol. 24, 187-192 (1989).
67. Inaba, M. et al. Evaluation of antitumor activity in a human breast tumor/nude mouse model with a special emphasis on treatment dose. Cancer 64, 1577-1582 (1989).
68. Soffer, S. Z. et al. Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor. J. Pediatr. Surg. 36, 1177-1181 (2001).
69. Soffer, S. Z. et al. Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor. J. Pediatr. Surg. 36, 1781-1784 (2001).
70. Zhang, L. et al. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose Doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis. Cancer Res. 62, 2034-2042 (2002).
71. Abraham, D., Abri, S., Hofmann, M., Hoitl, W. & Aharinejad, S. Low dose carboplatin combined with angiostatic agents prevents metastasis in human testicular germ cell tumor xenografts. J. Urol. 170, 1388-1393 (2003).
72. Svensson, A., Backman, U., Jonsson, E., Larsson, R. & Christofferson, R. CHS 828 inhibits neuroblastoma growth in mice alone and in combination with antiangiogenic drugs. Pediatr. Res. 51, 607-611 (2002).
73. Petrangolini, G. et al. Antiangiogenic effects of the novel camptothecin ST1481 (gimatecan) in human tumor xenografts. Mol. Cancer Res. 1, 863-870 (2003).
74. Yonekura, K. et al. UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. Clin. Cancer Res. 5, 2185-2191 (1999).
75. Yu, J. L., Rak, J. W., Coomber, B. L., Hicklin, D. J. & Kerbel, R. S. Effect of p53 status on tumor response to antiangiogenic therapy. Science 295, 1526-1528 (2002).
76. Huang, J. et al. Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol. Cancer Res. 2, 36-42 (2004).
77. Belotti, D. et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res. 2, 1843-1849 (1996).
78. Bocci, G., Nicolaou, K. C. & Kerbel, R. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res. 62, 6938-6943 (2002). Selective inhibition of human endothelial-cell proliferation or induction of apoptosis was detected only after a prolonged exposure to very low concentrations of a number of different chemotherapeutic drugs, including taxanes and alkylating agents.
79. Vacca, A. et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 94, 4143-4155 (1999). One of the first studies to show that ultra-low concentrations of the conventional chemotherapeutic drug vinblastine could selectively affect endothelial-cell functions relevant to angiogenesis.
80. Wang, J., Lou, P., Lesniewski, R. & Henkin, J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 14, 13-19 (2003). An important study showing that low concentrations of paclitaxel selectively inhibit human vascular endothelial-cell proliferation in vitro, whereas non-endothelial cell types were inhibited by higher drug concentrations.
81. Grant. D. S., Williams. T. L., Zahaczewsky, M. & Dicker, A. P. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int. J. Cancer 104, 121-129 (2003).
82. Ng, S. S., Figg, W. D. & Sparreboom, A. Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins. Cancer Res. 64, 821-824 (2004).
83. de Fraipont, F., Nicholson, A. C., Feige, J. J. & Van Meir, E. G. Thrombospondins and tumor angiogenesis. Trends. Mol. Med. 7, 401-407 (2001).
84. Lawler, J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J. Cell Mol. Med. 6, 1-12 (2002).
85. Dawson, D. W. et al. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J. Cell Biol. 138, 707-717 (1997).
86. Guo, N., Krutzsch, H. C., Inman, J. K. & Roberts, D. D. Thrombospondin 1 and type 1 repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res. 51, 1735-1742 (1997).
87. Jimenez, B. et al. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nature Med. 6, 41-48 (2000).
88. Gupta, K., Gupta, P., Wild, R., Ramakrishnan, S. & Hebbel, R. P. Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: effect on human microvascular endothelial cell proliferation and angiogenesis. Angiogenesis 3, 147-158 (1999).
89. Viloria-Petit, A. M. et al. Neutralizing antibodies against EGF and ErbB-2/neu receptor tyrosine kinases down-regulate VEGF production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol. 151, 1523-1530 (1997).
90. Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D. & Jain, R. K. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416, 279-280 (2002).
91. Asahara, T. et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275, 964-967 (1997).
92. Garcia-Barros, M. et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300, 1155-1159 (2003).
93. Rafil, S., Lyden, D., Benezra, R., Hattori, K. & Heissig, B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nature Rev. Cancer 2, 826-835 (2002).
94. Ruzinova, M. B. et al. Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell 4, 277-289 (2003).
95. Sikder, H. et al. Disruption of Id1 reveals major differences in angiogenesis between transplanted and autochthonous tumors. Cancer Cell 4, 291-299 (2003).
96. Takahashi, T. et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nature Med. 5, 434-438 (1999).
97. Heeschen, C. et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102, 1340-1346 (2003).
98. Lyden, D. et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nature Med. 7, 1194-1201 (2001).
99. Muta, M. et al. Impact of vasculogenesis on solid tumor growth in a rat model. Oncol. Rep. 10, 1213-1218 (2003).
100. Brower, V. Epoetin for cancer patients: a boon or a danger? J. Natl Cancer Inst 95, 1820-1821 (2004).
101. Masferrer, J. L. et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60, 1306-1311 (2000).
102. Gately, S. & Kerbel, R. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog. Exp. Tumor Res. 37, 179-192 (2003).
103. DiPaola, R. S., Durivage, H. J. & Kamen, B. A. High time for low-dose prospective clinical trials. Cancer 98, 1559-1561 (2003).
104. Mancuso, P. et al. Circulating endothelial cells in preclinical cancer models and in cancer patients: origin, kinetics and viability after conventional-dose or metronomic chemotherapy. Proc. Am. Assoc. Cancer Res. A2051 (2003).
105. Willett, C. G. et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Med. 10, 145-147 (2004).
106. Ben-Efraim, S. Immunomodulating anticancer alkylating drugs: targets and mechanisms of activity. Curr. Drug Targets 2, 197-212 (2001).
107. Matar, P., Guillermo, G., Celoria, C., Font, M. T. & Scharovsky, O. G. Antimetastatic effect of a single-low dose of cyclophosphamide on a rat lymphoma. J. Exp. Clin. Cancer Res. 14, 59-63 (1995).
108. Hermans, I. F., Chong, T. W., Palmowski, M. J., Harris. A. L. & Cerundolo, V. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res. 63, 8408-8413 (2003). An important study illustrating the potential benefits of combining a non-immunosuppressive metronomic weekly cyclophosphamide regimen with an immunotherapeutic approach to treat cancer. This circumvents the contra-indicated use of immunosuppresive MTD cytotoxic drug regimens with immunotherapy.
109. Dunussi-Joannopoulos, K. The combination of chemotherapy and systemic immunotherapy and the concept of cure in murine leukemia and lymphoma. Leuk. Lymphoma 43, 2075-2082 (2002).
110. Wu, L. & Tannock, I. F. Repopulation in murine breast tumors during and after sequential treatments with cyclophosphamide and 5-fluorouracil. Cancer Res. 63, 2134-2138 (2003).
111. Rubie, H. et al. Localised and unresectable neuroblastoma in infants: excellent outcome with low-dose primary chemotherapy. Br. J. Cancer 89, 1605-1609 (2003).
112. Azzarelli, A. et al. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer 92, 1259-1264 (2001).
113. Lamont, E. B. & Schilsky, R. L. The oral fluoropyrimidines in cancer chemotherapy. Clin. Cancer Res. 5, 2289-2296 (1999).
114. Hoff, P. M., Pazdur, R., Benner, S. E. & Canetta, R. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. Anticancer Drugs 9, 479-490 (1998).
115. Friedman, M. Of what value is uracil/tegafur plus leucovorin to colorectal cancer patients? J. Clin. Oncol. 20, 3574-3575 (2002).
116. Kato, H. et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N. Engl. J. Med. 350, 1713-1721 (2004). The results of an important Phase III trial to test adjuvant chemotherapy in patients with early stage lung cancer using a 5-fluoruracil prodrug called uracil plus tegafur. This drug was administered orally at low dose every day for two years, with no breaks. This could be an example, in retrospect, of a metronomic chemotherapy regimen with validated efficacy.
117. Yonekura, K. et al. UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. Clin. Cancer Res. 5, 2185-2191 (1999).
118. Newlands, E. S., Stevens, M. F., Wedge, S. R., Wheelhouse, R. T. & Brock, C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat. Rev. 23, 35-61 (1997).
119. Kurzen, H., Schmitt, S., Naher, H. & Mohler, T. Inhibition of angiogenesis by non-toxic doses of temozolomide. Anticancer Drugs 14, 515-522 (2004).
120. Niitsu, N. & Umeda, M. Evaluation of long-term daily administration of oral low-dose etoposide in elderly patients with relapsing or refractory non-Hodgkin's lymphoma. Am. J. Clin. Oncol. 20, 311-314 (1997).
121. Braybrooke, J. P. et al. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clin. Cancer Res. 6, 4697-4704 (2000).
122. Danson, S. et al. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon α-2b or thalidomide in metastatic malignant melanoma. J. Clin. Oncol. 21, 2551-2557 (2003).
123. Hwu, W. J. et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J. Clin. Oncol. 21, 3351-3356 (2003).
124. Malingre, M. M., Beijnen, J. H. & Schellens, J. H. Oral delivery of taxanes. Invest. New Drugs 19, 155-162 (2001).
125. Pastorino, F. et al. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res. 63, 7400-7409 (2003).
126. Mauceri, H. J. et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394, 287-291 (1998).
127. Wachsberger, P., Burd, R. & Dicker, A. P. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin. Cancer Res. 9, 1957-1971 (2003).
128. Kaban, L. B. et al. Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon α-2a. Pediatrics 103, 1145-1149 (1999).
129. Ezekowitz, R. A., Mulliken, J. B. & Folkman, J. Interferon α-2a therapy for life-threatening hemangiomas of infancy. N. Engl. J. Med. 326, 1456-1463 (1992).
130. Slaton, J. W., Perrotte, P., Inoue, K., Dinney, C. P. & Fidler, I. J. Interferon-α-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin. Cancer Res. 5, 2726-2734 (1999).
131. Eisenhauer, E. A. Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel Lecture. Ann. Oncol. 9, 1047-1052 (1998).
132. Cristofanilli, M., Charnsangavej, C. & Hortobagyi, G. N. Angiogenesis modulation in cancer research: novel clinical approaches. Nature Rev. Drug Discov. 1, 415-426 (2002).
133. Wolf, W., Presant, C. A., Waluch, V. & Le Berthon, B. J. Response to anticancer treatment with Docetaxel (DOC) administered every 3 weeks (Q3w) and weekly (Q1w) is associated with functional assessment of changes in tumoral blood flow/perfusion. Proc. Am. Assoc. Cancer Res. A5343 (2003).
134. Morgen, B. et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J. Clin. Oncol. 21, 3955-3964 (2003).
135. Rabascio, C. et al. Assessing tumour angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells. Cancer Res. (in the press).
136. + lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J. Clin. Oncol. 22, 610-616 (2004).
137. Kaur, H. & Budd, G. T. Metronomic therapy for breast cancer. Curr. Oncol. Rep. 6, 49-52 (2004).
138. Kieran, M. W. Anti-angiogenic chemotherapy in central nervous system tumors. Cancer Treat. Res. 117, 337-349 (2004).
139. Gluck, S. et al. Metronomic therapy in recurrent and metastatic chemo-resistant SCCHN: Data from a pilot study. Proc. Am. Soc. Clin. Oncol. 22, A2066 (2003).
140. Buckstein, R. et al. High dose celecoxib and low dose cyclophosphamide for relapsed aggressive histology NHL Proc. Am. Soc. Clin. Oncol. 22, A827 (2003).
141. Bjarnason, G. A. et al. Phase II trial of continuous low dose cyclophosphamide and celecoxib in patients with progressing advanced renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol. 22, A17 (2003).
142. Bergers, G. & Hanahan, D. Combining antiangiogenic agents with metronimoic chemotherapy enhances efficacy against late-stage pancreatic islet carcinomas in mice. Cold Spring Harb. Symp. Quant. Biol. 67, 293-300.